SMBG Market in India 2013

SMBG Market in India 2013

SMBG equipments has witnessed strong growth over the last few years on account of large number of diabetics and increasing awareness towards SMBG. People are also becoming aware of the harmful effects of diabetes.

The report begins with macro economic indicators whereby the basic economic indicators have been depicted. In the introduction section market size of point of care testing for both global and Indian market has been provided. The advantages of point of care testing have been listed. The next slide provides the segmentation of the point of care market in India. In the market overview section market size and growth rate of SMBG in value terms has been provided. Further an overview of the harmful aspects of diabetes and promotion adopted by companies has been described. Factors affecting the use of SMBG and working principle of SMBG has been tabulated. The slide also enumerates the benefits of using SMBG. In the next slide the distribution channel of SMBG has been highlighted (both traditional and modern) along with indicative pricing.

Inquire about this report: SMBG Market in India 2013

In the next section drivers and challenges of SMBG market has been explained. Drivers include a large number of diabetic patients in India and a steady growth in their numbers in days to come. So it provides a market to grow for the manufacturers. Also rise in obese people has also provided a lucrative market to SMBG manufacturers. Demand for SMBG equipments are also in rise as people have become more health conscious. They have become aware of the danger diabetes poses. The challenges of SMBG market include not being able to buy SMBG for a large number of people who continue to suffer from diabetes. Moreover, this instrument also requires recurring expenditure in form of strips. Many a times people have problems in understanding the results of the test as they are unable to detect the color change. Many doctors are also skeptical about the results obtained from SMBG.

Trends of SMBG market include technological innovations being brought about by the manufacturers so as to make the product even more user friendly. Alternative bloodless glucometers are likely to hit the market as some people do not want to prick themselves. Again, glucometers are easily available in the chemist shop helping to increase penetration and hence the market of SMBG. Better insurance coverage has also helped SMBG market to grow.

The competition section begins with a Porter’s five forces model which analyses the dynamics of the market. The major players in the market have been profiled which includes a financial summary for each of the players. Key ratios and key contacts are also listed. The last section offers strategic recommendations for the players in the SMBG market. For each of the companies a SWOT analysis has been provided.

Companies covered in this market research report are-

Public Companies-

Abbott India Ltd., Bayer Crop Science Ltd.

Private Companies -

Arkray Healthcare Pvt. Ltd., Roche Diagnostics India Pvt. Ltd., Johnson and Johnson Ltd.

China Pharmaceutical Guidebook Series (3) 2013 Edition - Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products

The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and complex. In China, the development of biopharmaceutical industry is far behind the developed countries. The requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and harmonized. 

In China, the pharmaceutical regulatory authority - the SFDA (State Food and Drug Administration, China) divided the biopharmaceuticals for registration application into two classifications, i.e. the therapeutic biological products and the prophylactic biological products. However, in the classification of therapeutic biological products, the SFDA does not provide the uniform requirements of materials and clinical trials for application of biological products for the gene therapy, the somatic cell therapy and the allergic therapy, but stipulates the other guidelines for them respectively. These guidelines provide only a general principle for them because of their diversity and complexity. Just for this reason, a comprehensive and thorough knowledge of the latest Chinese regulations for imported biological product registration is particularly important  for overseas pharmaceutical manufacturers and producers to achieve a successful application for their products entry into the Chinese drug market.

This is the third guidebook of the China Pharmaceutical Guidebook Series. It provides a detailed introduction of SFDA’s requirements for materials and clinical trials of registration application and approval for imported biological products. This guidebook will introduce SFDA’s requirements for materials and clinical trials of registration application for imported biological products in four parts and twelve chapters according to the existing a serial of regulations and guidelines. The Part I provides an introduction of the requirements for materials and clinical trials of registration application for imported therapeutic biological products. The Part II introduces the requirements for materials and clinical trials of registration application for imported prophylactic biological products. The Part III addresses the requirements for materials and clinical trials of registration application for imported gene therapeutic biological products and somatic cell therapeutic biological products. The Part IV addresses the requirements for materials and clinical trials of registration application for imported allergic therapeutic biological products.

The guidebook concludes in chapter 13 by highlighting the significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their biopharmaceuticals registration in China. Last, the appendices in chapter 14 include the Drug Administration Law of the People’s Republic of China, the Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Form of Registration Application for Imported Drug, references, and description of Access China Management Consulting Ltd. After have skimmed through this guidebook, audience can be clearly aware of the latest Chinese regulations on requirements of the materials and the clinical trials for registration application of imported biological products. For the detailed pathway and procedure for application and approval of imported biological products, audience can learn from the first guidebook of the China Pharmaceutical Guidebook Series (2013 Edition) - Latest Chinese Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies.

Report Highlights:

• The classification of biological product registration
• The material items for application of biological product registration
• The requirements of material items for application of biological product registration
• The requirements of clinical trial for application of biological product registration
• The guideline for application of biological products for human gene therapy
• The guideline for application of biological products for somatic cell therapy
• The guideline for application of biological products for allergic therapy
• The significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their biopharmaceuticals registration in China.
• Many useful resources of law and regulations, including the Drug Administration Law of the People’s Republic of China, the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Form of Registration Application for Imported Drug, and so on.

Who should buy this market research report? 

• Companies wishing to enter a lucrative drug market in China.
• Companies interested in understanding the latest Chinese regulations on application and approval for imported drug registration. 
• Senior executive officers engaging regulatory and registration affairs for drugs.

Inquire about this report:

China Pharmaceutical Guidebook Series (3) 2013 Edition - Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Product

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013

B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
• A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Bronchopulmonary Dysplasia - Pipeline Review, H1 2013

Bronchopulmonary Dysplasia Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bronchopulmonary Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia. Bronchopulmonary Dysplasia Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Bronchopulmonary Dysplasia.
• A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Bronchopulmonary Dysplasia pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Friedreich Ataxia - Pipeline Review, H1 2013

Friedreich Ataxia Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Friedreich Ataxia. Friedreich Ataxia Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Friedreich Ataxia.
• A review of the Friedreich Ataxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Friedreich Ataxia pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Friedreich Ataxia.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Friedreich Ataxia pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Secondary Hyperparathyroidism - Pipeline Review, H1 2013

Secondary Hyperparathyroidism Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Secondary Hyperparathyroidism Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Secondary Hyperparathyroidism.
• A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Secondary Hyperparathyroidism pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Burkitt Lymphoma - Pipeline Review, H1 2013

Burkitt Lymphoma Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma. Burkitt Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Burkitt Lymphoma.
• A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Burkitt Lymphoma pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Percutaneous Coronary Intervention - Pipeline Review, H1 2013

Percutaneous Coronary Intervention Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Percutaneous Coronary Intervention, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Percutaneous Coronary Intervention. Percutaneous Coronary Intervention Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Percutaneous Coronary Intervention.
• A review of the Percutaneous Coronary Intervention products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Percutaneous Coronary Intervention pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Percutaneous Coronary Intervention.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Percutaneous Coronary Intervention pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Thymus Cancer - Pipeline Review, H1 2013

Thymus Cancer Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thymus Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thymus Cancer. Thymus Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Thymus Cancer.
• A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Thymus Cancer pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Thymus Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Anesthetic Effect - Pipeline Review, H1 2013

Anesthetic Effect Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anesthetic Effect, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anesthetic Effect. Anesthetic Effect Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Anesthetic Effect.
• A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Anesthetic Effect pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2013

Athlete's Foot (Tinea Pedis) Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Athlete's Foot (Tinea Pedis) Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Athlete's Foot (Tinea Pedis).
• A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Athlete's Foot (Tinea Pedis).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Athlete's Foot (Tinea Pedis) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Cardiomyopathy - Pipeline Review, H1 2013

Cardiomyopathy Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiomyopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiomyopathy. Cardiomyopathy Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Cardiomyopathy.
• A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Cardiomyopathy pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2013

Chagas Disease (American Trypanosomiasis) Pipeline Review, H1 2013 report provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis). Chagas Disease (American Trypanosomiasis) Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

• A snapshot of the global therapeutic scenario for Chagas Disease (American Trypanosomiasis).
• A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

 

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.